Our Board Directors

David McTurk - JDRF Chair

I am an electronics engineer by training and have been deeply involved in building advanced technology manufacturing businesses for most of my career. I also have my own Change Management company.  My daughter, Sarah, was diagnosed with type 1 when she was 11 which was life changing for the whole family and the condition has been a significant influence on our lives ever since, bringing some bad times but also a lot of inner strength to all of us.  I have been involved with JDRF since 2002 and first served on the Board from then until 2008 when I became Chair of the Trading Company.  I re-joined the Board in March 2017 and became its Chair in January 2019.  I love JDRF for what it does, for the purity of its mission, and for the terrific team, led by the extraordinary and inspiring CEO, Karen.  I know we will rid the world of type 1 diabetes and being part of this mission is deeply important to me and to all of us. 

Board member - Ian Schneider
Ian Schneider

JDRF Treasurer, Executive Committee Member, Former Partner at PwC and a Chartered Accountant. I have type 1 diabetes and was diagnosed over 40 years ago. I am now starting to confront some of the wider medical issues arising from having had type 1 for an extended period and realistically, given my age, I don't see a personal benefit from a type 1 cure. However I feel very passionate about achieving a cure so that others do not have to deal with managing that delicate blood sugar level balance, or cope with the consequences when it goes wrong. This extends beyond those who have type 1 to all those who love and live with them. If we can put a man on the moon...

Phil Aird-Mash

Chief Executive Officer of ITC Travel Group, Chairman of ACC Aviation and JDRF Board Director. I have lived with type 1 diabetes since I was 28 and consider myself fortunate that I was diagnosed swiftly and with great support from healthcare professionals and my family and friends. Since this time, I have always given much thought to the impact type 1 has on families, and in particular on children who are diagnosed with the condition. JDRF’s research to find a cure, alongside its work to support and improve the health, well being and quality of life of those affected, has tremendous personal resonance. I am delighted to be able to use my skills, experience and networks to help the cause.

Barrie Brien

Group CEO of STRAT7, a data driven strategy group; plus Non-Executive Chair, Director and Board Advisor to a portfolio of public and private companies and Board Director of JDRF.  I have spent thirty years working in global media and marketing groups holding a variety of senior roles in the UK, Europe and North America.  I was first introduced to JDRF ten years ago, when my niece was diagnosed with type 1 diabetes.  In 2014, my nine year old son was also then diagnosed and the condition has become an everyday battle for both our families.  I am delighted to be part of the JDRF team to achieve its very clear mission of improving the lives of those afflicted by type 1 as well as finding a cure as quickly as possible.

JDRF Board Director
Jared Chebib

I’m an Associate Partner at EY, and work as a management consultant in financial services. I joined JDRF’s Board in December 2020 as the Treasurer-elect. My younger daughter Emily was diagnosed with type 1 diabetes when she was six. In the two years since, we’ve learned first hand about the impact type 1 diabetes has on children and their families. We’ve also learned how big a difference it makes to have the support of a great medical team, and the resources and hope that JDRF provides. I’m very pleased to have joined the JDRF team. And I believe that, together, we can make a huge difference to reduce the daily burden of type 1 diabetes on those it affects directly and their families.

Christina Croft

International banker with corporate finance and private banking experience; JDRF Board Director and Director of JDRF Trading Ltd. One of my daughters, Alexandra, has lived with type 1 diabetes for many years. Following her diagnosis our family wanted to learn as much as possible about the condition and contribute in some way to finding the cure which is why we got in touch with JDRF. This is the second term I have served on the Board and it's exciting to see how much JDRF as an organisation has developed and the great strides that have been made within research that will help cure, treat and prevent type 1. It's a hugely exciting time to be part of JDRF's work and I am honoured to have been asked to serve a second term.

Wilson Leech

An experienced Chief Executive, Chief Financial Officer and Chief Operating Officer who has worked in financial services throughout his career.  I was diagnosed with type 1 diabetes when I was 16, some 40 or so years ago, when I was very focused on school and future careers.  Despite the disruption, I went on to university where I took Business Studies, and subsequently qualified as an accountant.  I joined JDRF UK's Board in December 2020 and also served as a JDRFI Director on theIllinois Chapter’s Board when I lived in the United States.  When I was planning my return to the UK, I asked to be introduced to the team here so I could continue to support the Charity's amazing work.  I am particularly interested in type 1 technology and ensuring everyone has access to the best treatments and devices for them.  I also look forward to carrying on my work to support members of our fundraising department.  

Dr Per Lundin

Co-Founder and Chief Operating Officer of Evox Therapeutics Ltd, an Oxford-based exosome therapeutics company; Non-Executive Director of viral gene therapy company Combigene (COMBI); and Board Director of JDRF. I was diagnosed with type 1 in my mid 20s while completing my PhD. Despite having a good scientific understanding of the condition and having had family members with diabetes, one cannot really be prepared for the impact of a diagnosis. Having spent a large part of my career advising, founding and leading biotech companies working to develop advanced therapies against diseases of high unmet medical need I have seen first-hand the importance of charities in funding research, supporting patients and their families, and ultimately accelerating the development of curative therapies. In this era of remarkable pharmaceutical and biotechnology innovation I am excited to be able to contribute to JRDF’s mission to develop a cure for type 1 diabetes, a goal that is closer than it has ever been before.

James M Lurie
James M Lurie

Corporate Attorney and Partner at Wollmuth Maher & Deutsch, JDRF Board Director - My brother and niece both have type 1 diabetes. The cure would be a dream come true for our family, the completion of a sacred promise I made to my brother and parents that I wouldn’t stop until a cure is found. Not to have to worry about complications, about daily shots and blood testing. To see the smile on my niece’s face that she no longer has to worry about any of these things. But what will be the cure? What ‘cures’ my brother and niece and others with type 1 diabetes may necessitate different remedies and then how do we be make sure that my and my brother’s grandchildren don’t become afflicted with type 1 diabetes? The research must go on. We need your help. There is a cure out there and together we can and will find it.